Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In these disorders, instead of protecting the body, the body attacks itself. The immune system mistakes some part of the body as a pathogen and creates a defense. This may be restricted to certain organs (e.g. in chagas disease) or involve a particular tissue in different places (e.g. Goodpasture's disease which may affect the basement membrane in both the lung and the kidney). The treatment of autoimmune diseases is typically with immunosuppression—medication which decreases the immune response. Immunosuppressants are many and there is considerable research and development going on in this area.
Classification of autoimmune disorders is still somewhat controversial, but the following criteria is generally accepted: Direct evidence from transfer of pathogenic antibody or pathogenic T cells, indirect evidence based on reproduction of the autoimmune disease in experimental animals, and circumstantial evidence from clinical clues
Arthritis is among the most common autoimmune disorders. Arthritis is joint inflammation The major complaint by individuals who have arthritis is joint pain. Pain is often a constant and may be localized to the joint affected. There are over one hundred forms different forms The most common form, osteoarthritis (degenerative joint disease) is a result of trauma to the joint, infection of the joint, or age. Other arthritis forms are rheumatoid arthritis, psoriatic arthritis, and related autoimmune diseases. Septic arthritis is caused by joint infection. Treatment options vary depending on the type of arthritis and include physical therapy, exercise and weight control, bracing, medications. Surgery may be required in some changes.
Classification of autoimmune disorders is still somewhat controversial, but the following criteria is generally accepted: Direct evidence from transfer of pathogenic antibody or pathogenic T cells, indirect evidence based on reproduction of the autoimmune disease in experimental animals, and circumstantial evidence from clinical clues
Arthritis is among the most common autoimmune disorders. Arthritis is joint inflammation The major complaint by individuals who have arthritis is joint pain. Pain is often a constant and may be localized to the joint affected. There are over one hundred forms different forms The most common form, osteoarthritis (degenerative joint disease) is a result of trauma to the joint, infection of the joint, or age. Other arthritis forms are rheumatoid arthritis, psoriatic arthritis, and related autoimmune diseases. Septic arthritis is caused by joint infection. Treatment options vary depending on the type of arthritis and include physical therapy, exercise and weight control, bracing, medications. Surgery may be required in some changes.
All reports in Autoimmune
|
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
... its latest research “Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments”, which provides insights into autoimmune disease therapeutics ...
|
more...
|
$3,500.00
|
|
Systemic Lupus Erythematosus – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. 'Systemic Lupus ...
|
more...
|
$500.00
|
|
Psoriasis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. 'Psoriasis - Pipeline Review, H1 2012' is built using data and information ...
|
more...
|
$500.00
|
|
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
2/14/2012 | published by: GBI Research
... Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success” which provides an insight into different endpoints used in clinical trials in autoimmune disorders. The report examines ...
|
more...
|
$3,500.00
|
|
Liver Disease Treatments: The Global Market
1/1/2012 | published by: BCC Research
... stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors). The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016. The U.S. ...
|
more...
|
$4,850.00
|
|
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
12/5/2011 | published by: GlobalData
... essential source of information and analysis on the global Celiac Disease Therapeutics market. The report identifies the key trends shaping and driving the global Celiac Disease Therapeutics market. The report also provides insights on the ...
|
more...
|
$3,500.00
|
|
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
12/1/2011 | published by: GBI Research
... research “Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market” which provides insights about monoclonal antibodies sales forecasts until 2017. Monoclonal ...
|
more...
|
$3,500.00
|
|
Auto Inflammatory Disease - Pipeline Review, H2 2011
11/28/2011 | published by: Global Markets Direct
... the therapeutic development for Auto Inflammatory Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Auto Inflammatory Disease. 'Auto Inflammatory ...
|
more...
|
$500.00
|
|
Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2011
11/28/2011 | published by: Global Markets Direct
... provides information on the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acquired ...
|
more...
|
$500.00
|
|
Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market
11/22/2011 | published by: GBI Research
... by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market” provides in-depth analysis of the drivers and barriers that affect the global orphan autoimmune disorders. The report analyzes the markets ...
|
more...
|
$3,500.00
|
|
Neuromodulation Devices: World Market Prospects 2011-2021
10/5/2011 | published by: Visiongain
... the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict ...
|
more...
|
$2,642.00
|
|
Drugs and Treatments for Autoimmune Diseases: Global Markets
10/1/2011 | published by: BCC Research
... annual growth rate (CAGR) of 7.2%. U.S being the largest market for autoimmune treatments holds 43% share in the global market, it will sustain its position and will hold 44% market share in 2016. Europe ...
|
more...
|
$4,850.00
|
|
Celiac Disease - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... for Celiac Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Celiac Disease. 'Celiac Disease - Pipeline Review, H2 2011' ...
|
more...
|
$500.00
|
|
Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth
9/17/2011 | published by: GBI Research
... Diseases and Neurological Disorders Stimulate Market Growth” provides in-depth analysis of the, drivers and barriers that affect the global immunoglobulins market. The report analyzes the markets for immunoglobulins products in the US, the top five ...
|
more...
|
$3,500.00
|
|
Autoimmune Market Access in China - New biologic therapies drive future growth
9/14/2011 | published by: Datamonitor
... were analyzed. Recent deals and alliances were presented and strategic recommendations to enter the Chinese autoimmune market were proposed.Quantify the prevalent cases of rheumatoid arthritis, inflammatory bowel diseases (ulcerative colitis and Crohn’s disease), and psoriasis ...
|
more...
|
$5,700.00
|
|
Autoimmune Market Access in China – New biologic therapies drive future growth
9/14/2011 | published by: Datamonitor
... conducted an epidemiological review of three key autoimmune disorders and reviewed the organization and delivery of autoimmune services in China. Key products and strategies of both domestic and multinational companies active in the market were ...
|
more...
|
$5,700.00
|
|
Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment Per Trial has Continued to Decline Over the Past Decade
9/1/2011 | published by: GBI Research
... Autoimmune Disorders-Average Patient Recruitment per Trial has Continued to Decline Over the Past Decade” which provides an insight into clinical trial and patient recruitment in Autoimmune Disorders. The report examines different aspects concerning clinical trial ...
|
more...
|
$3,500.00
|
|
Report: Do the Emerging Treatments for Celiac Disease Offer Significant Improvements over the Gluten-Free Diet?
9/1/2011 | published by: Decision Resources
... these patients-a gluten-free diet. Interviewed experts watch with interest the clinical development of other therapies for celiac disease patients. This market presents a substantial opportunity for drug developers. Questions Answered * A gluten-free diet is ...
|
more...
|
$9,200.00
|
|
Strategic Overview of the Autoimmune Biologics Market
9/1/2011 | published by: Decision Resources
... inhibitors-Amgen/Pfizer/Takeda's Enbrel (etanercept), Janssen Biotech/Merck & Co./Mitsubishi Tanabe's Remicade (infliximab), Abbott/Eisai's Humira (adalimumab), Janssen Biotech/Merck & Co./Mitsubishi Tanabe/Janssen's Simponi (golimumab), and UCB/Otsuka's Cimzia (certolizumab pegol)-have been successful in treating many patients with certain autoimmune disorders. ...
|
more...
|
$4,600.00
|
|
Chronic Plaque Psoriasis - Pipeline Review, H2 2011
8/31/2011 | published by: Global Markets Direct
... the therapeutic development for Chronic Plaque Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis. 'Chronic Plaque ...
|
more...
|
$500.00
|
|
Special Report: The Autoimmune Biologics Pipeline—A Competitive Review
8/1/2011 | published by: Decision Resources
... opportunity for developers of biologics to discover and develop biologics with different targets. For example, increased levels of interleukin-6 (IL-6) have been found in patients with rheumatoid arthritis (RA) and Crohn's disease (CD), making this ...
|
more...
|
$9,200.00
|
|
Special Report: The Pricing and Reimbursement Environment for Autoimmune Biologics
8/1/2011 | published by: Decision Resources
... Japan) will grow from 19 million in 2010 to 20.7 million in 2020, an increase of 9% in ten years. Many of these patients will be candidates for biologic therapy, but the high cost of ...
|
more...
|
$9,200.00
|
|
ProtAb Private Vendor Watchlist Profile: Therapeutic Antibodies for Treating Autoimmune Diseases
6/29/2011 | published by: IDC
... success factors: market potential, technology/solution, corporate strategy, force multipliers, and customers. Leveraging IDC's expert understanding of the competitive landscape and future outlook, this document highlights company and market information tailored to the investment professional's needs.
|
more...
|
$3,000.00
|
|
Product Profiles: Systemic Lupus Erythematosus - Benlysta approval brings lessons and hope to market
6/27/2011 | published by: Datamonitor
... program of Benlysta are already being applied to additional drug candidates, and large-scale international trials are becoming the norm. Features and benefits Access Datamonitor’s independent clinical and commercial assessment of off-label, marketed, and pipeline candidates ...
|
more...
|
$11,400.00
|
|
Chronic Plaque Psoriasis Global Clinical Trials Review, Q2, 2011
6/24/2011 | published by: GlobalData
... provides elemental information and data relating to the clinical trials on Chronic Plaque Psoriasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ...
|
more...
|
$1,000.00
|


